Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1989-09-14
1992-05-12
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 4, 514 12, 514 13, 514 14, 514 15, 514947, 514970, 424434, A61K 900, A61K 3726, A61K 3702
Patent
active
051128047
ABSTRACT:
A composition and method for nasal administration of pharmaceuticals utilizes glycyrrhetinic acid as an absorption enhancer. The composition comprises an effective amount of the pharmaceutically active substance, glycyrrhetinic acid, in an amount effective for enhancing permeation of the active substance across the nasal membrane, and a basic salt of an amino acid as an adjuvant. The composition may be administered to the nasal cavity in the form of a spray by using an atomizer, nebulizer, spayer, dropper or other device which ensures contact of the composition with the nasal mucus membrane.
REFERENCES:
patent: 3944660 (1976-03-01), Gottfried et al.
patent: 4153689 (1979-05-01), Hira et al.
patent: 4294829 (1981-10-01), Suzuki
patent: 4476116 (1984-10-01), Anik
patent: 4517173 (1985-05-01), Kizawa et al.
patent: 4568343 (1986-02-01), Leeper
patent: 4743588 (1988-05-01), Mirejovsky
patent: 4764379 (1988-08-01), Sanders
patent: 4820720 (1989-04-01), Sanders
patent: 4835142 (1989-05-01), Suzuki et al.
patent: 4865848 (1989-09-01), Cheng
patent: 4873266 (1989-10-01), Leonard
patent: 4888360 (1989-12-01), Leonard
patent: 4888362 (1989-12-01), Leonard
patent: 4933169 (1990-06-01), Shanbrom
The Merck Index, 11th ed., Merck and Co., 1989, Entry Nos. 3543, 4401, pp. 562 and 708.
Chemical Abstract 95:28229n (Feb. 1, 1982) abstracting Yaginuma et al. "The Influence of Anti-inflammatory Drugs on Rectal Absorption of .beta.-lact Antibiotics", Chem. Pharmaceutical Bulletin 29 (10), 2974-89 (1981).
Medline Abstract 89258205, abstracting Mishima M. et al., "Promotion of Nasal Absorption of Insulin by Glycyrrhetinic Acid Derivatives", J. Pharmacobiodyn 12 (1), 31-6 (Jan. 1989).
Salzman et al., Intranasal Aerosolized Insulin, New England Journal of Medicine, pp. 1078-1084 (Apr. 25, 1985).
Gordon et al., Nasal absorption of Insulin: Enhancement by hydrophobic bile salts, Medical Sciences, 85 7419-7423, Nov. 1985.
Moses et al., Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol, Diabetes 32, 1040-1047, Nov. 1983.
Hirai, The International Journal of Pharmaceuticals, 9, 165-172 (1981).
The Merck Index, 9th ed., Merck & Co., Inc., 1976, entry Nos. 470 and 4369, p. 647.
Pontiroli, British Medical Journal 284, 303-306 (1982).
Fieser & Fieser, Organic Chemistry (3rd Ed.), Reinhold Pub. Co. N.Y., N.Y. 113-115, 218, 353, 607, 622, 628, 635, 681-684 (1956).
Finar, Organic Chemistry, vol. 2, (6th Ed.), Longman, N.Y., N.Y., Chap. 1, pp. 4-5.
Hermens et al., Pharmaceutical Research, vol. 4, No. 6, 445-449, (1987).
Moezie F. T.
Temple University Of The Commonwealth System Of Higher Education
LandOfFree
Pharmaceutical composition and method of intranasal administrati does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition and method of intranasal administrati, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition and method of intranasal administrati will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2426161